Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease PatientsJuly 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients A biopharmaceutical company announced the results of a Phase 1b of CERC-002.Article from GlobeNewswireShare This Story, Choose Your PlatformFacebookTwitterLinkedInPinterestEmail Related Posts Stories From Our Region – March 2023 Stories From Our Region – February 2023 Stories From Our Region – January 2023 Stories From Our Region – December 2022 Stories From Our Region – November 2022
